Abstract Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma Background Approximately 75% of objective responses to anti–programmed death 1 (PD-1) therapy in patients with…smaggio28 Luglio 2017
Abstract Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial Summary Background Dabrafenib plus trametinib improves clinical outcomes in BRAFV600-mutant metastatic melanoma without brain metastases;…smaggio28 Luglio 2017
